New asthma drug candidate PA9159 passes first safety check in healthy volunteers
NCT ID NCT06916273
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new asthma medication called PA9159, given as an inhaled aerosol, in 40 healthy adults in China. The main goal was to see if it is safe and how the body processes it. Researchers monitored side effects, vital signs, and lab tests after single and repeated doses. This is a first step before testing the drug in people with asthma.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PA9159 (a novel corticosteroid) inhalation aerosol
What this could lead to
If successful, this could lead to a new inhaled corticosteroid for controlling asthma symptoms.
What could go wrong
This is an early Phase 1 safety trial in healthy people, not asthma patients. It only checks safety and dosing, not whether the drug works for asthma. Many early-stage drugs fail to show benefit later.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHIAL ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 330006, China